NEW YORK--(BUSINESS WIRE)--Medidata Solutions, a global provider of electronic clinical data capture, management and reporting solutions, today announced that Daiichi Pharmaceutical Co., Ltd. has chosen Medidata Rave for its ability to efficiently and cost-effectively manage multilingual clinical trials, and ultimately bring life-enhancing treatments to market faster. As Medidata Solutions’ first customer in the Japan market, Daiichi has successfully implemented six clinical trials, including a Phase II, 500-patient, 60-site study for a cardiovascular drug. Daiichi plans to continue to use Medidata Rave for additional Phase I, Phase II and Phase III studies in other therapeutic areas.
